Acquiring Company
Regeneron
Acquired Company
Checkmate Pharmaceuticals, Inc.
TarrytownCambridgeBiotechnologyHealth CareScience And EngineeringTherapeuticsBiotechnologyHealthcareHealth CareScience And EngineeringDescription
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has successfully acquired Checkmate Pharmaceuticals, Inc., deepening its commitment to immuno-oncology and adding a new modality to the company's portfolio of potential combination-ready approaches for difficult-to-treat cancers.
Quick answer
Regeneron is acquiring Checkmate Pharmaceuticals, Inc., announced May 31, 2022. Regeneron is based in Tarrytown, New York, United States.
- Who acquired Checkmate Pharmaceuticals, Inc?
- Regeneron agreed to acquire Checkmate Pharmaceuticals, Inc. on May 31, 2022.
- How much did Regeneron pay for Checkmate Pharmaceuticals, Inc?
- The deal value was not disclosed.
- What does Regeneron do?
- Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.
- Where are Regeneron and Checkmate Pharmaceuticals, Inc. based?
- Regeneron is based in Tarrytown, New York, United States. Checkmate Pharmaceuticals, Inc. is based in Cambridge, Massachusetts, United States.
Source: Fundz verified event record.
Other recent acquisitions in Science And Engineering and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Regeneron To Acquire Checkmate Pharmaceuticals And Its Investigational Immune Activator For Potential Use In Multiple Tumor Types (April 19, 2022)
- Aprea Therapeutics Announces Acquisition Of Atrin Pharmaceuticals Inc. And Reports First Quarter 2022 Financial Results (May 16, 2022)
- U.S. Alliance Pharma Acquires U.K.-Based Lgc’S Drug Development Solutions (Dds) Business (July 13, 2022)
- Pfizer To Acquire Biohaven Pharmaceuticals (May 10, 2022)
- Consegna Pharma Acquires Fathom Pharma To Strengthen Initiatives That Address The Opioid Crisis (April 19, 2022)
- Bristol Myers Squibb To Acquire Turning Point Therapeutics, A Leading Precision Oncology Company (June 3, 2022)
Who to call at Regeneron, and when
When Regeneron changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Regeneron raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Regeneron, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Regeneron. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Regeneron makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Checkmate Pharmaceuticals, Inc.?
Checkmate Pharmaceuticals, Inc. was acquired by Regeneron, based in Tarrytown. The deal was reported on May 31, 2022. Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Regeneron is publicly traded (REGN) and operates in Biotechnology.
When did Regeneron acquire Checkmate Pharmaceuticals, Inc.?
Regeneron's acquisition of Checkmate Pharmaceuticals, Inc. was reported on May 31, 2022. Regeneron Pharmaceuticals, Inc. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Checkmate Pharmaceuticals, Inc. do?
Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer. It is privately held, operating in Biotechnology, and is based in Cambridge.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.